case_images: PMC9893996_01
case_images: PMC9893996_02
case_images: PET scan December 2018 demonstrating recurrent unresectable metastatic disease in mediastinum (left) and flank (right). PET, positron emission tomography.
case_images: cro-2023-0016-0001-528743_f1.jpg
case_images: PMC9893996_02_cro-2023-0016-0001-528743_f1.jpg
case_images: F1
case_images: At the end of 2018, a positron emission tomography scan identified unresectable recurrence in the mediastinum and left flank (shown in Fig. 1).
case_images: PMC9893996_03
case_images: PMC9893996_04
case_images: PMC9893996_05
case_images: Radiological response with trametinib in perinephric/retroperitoneal lesions and mediastinal lesion at month 2 (a, b), 4 (c, d), and 7 (e, f).
case_images: cro-2023-0016-0001-528743_f2.jpg
case_images: PMC9893996_05_cro-2023-0016-0001-528743_f2.jpg
case_images: F2
case_images: Computerized tomography scans at month 2, 4, and 7 after commencement of trametinib showed response in all known sites of disease, retroperitoneal/perinephric lesion and mediastinal lesion (shown in Fig. 2).
case_images: PMC9893996_06
case_images: PMC9893996_07
case_images: Summary of systemic treatment in incurable setting for patient and times to progression.
case_images: cro-2023-0016-0001-528743_f3.jpg
case_images: PMC9893996_07_cro-2023-0016-0001-528743_f3.jpg
case_images: F3
case_images: In summary, the patient achieved response to disease at all sites on trametinib for 10 months, the most durable response of all his systemic treatments (shown in Fig. 3).